CLINICAL TRIAL: ADULT PATIENTS W/RELAPSED OR REFRACTORY B-LINEAGE ACUTE LYMPHOBL

临床试验：患有复发或难治性 B 系急性淋巴细胞的成年患者

• 批准号: 7717899
• 负责人: STEVEN E COUTRE
• 金额: $ 0.06万
• 依托单位: STANFORD UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-12-01 至 2008-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7717899
• 关键词: Acute; Adult; Antibodies; Cell Lineage; Clinical Trials; Complement; Computer Retrieval of Information on Scientific Projects Database; Drug Kinetics; Funding; Grant; Human; Immunoglobulin M; Institution; Lymphoblastic Leukemia; Monoclonal Antibodies; Patients; Phase I Clinical Trials; Refractory; Relapse; Research; Research Personnel; Resources; Safety; Source; United States National Institutes of Health; Vincristine; killings; tumor

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. A Phase I trial of a human IgM monoclonal antibody (MAb216) that kills B lineage cells including acute B lymphoblastic leukemia, with or without complement. Trial will study safety, pharmacokinetics and anti-tumor acitivity of the antibody given as a single agent and with vincristine in adult patients with relapsed or refractory B lineage ALL.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目和 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 人类 IgM 单克隆抗体 (MAb216) 的 I 期试验，可在有或没有补体的情况下杀死 B 谱系细胞，包括急性 B 淋巴细胞白血病。 试验将研究该抗体作为单药以及与长春新碱联合用药用于患有复发或难治性 B 系 ALL 的成年患者的安全性、药代动力学和抗肿瘤活性。